--- title: IQVIA (IQV) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/iqv ticker: IQV as_of: 2026-10-17 sector: Healthcare industry: Medical - Diagnostics & Research --- # IQVIA (IQV) IQVIA (IQV) closed at $266.90 on Oct 16, 2026, overvalued by 12% vs its model value of $237.57 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $266.90 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $237.57 | | Price vs model | overvalued by 12% vs model | | Range of that model | $131.30 – $621.45 | | Market value | $43.9B | | P/E (fiscal 2025) | 34.0 | | Net margin (fiscal 2025) | 8.3% | | Free cash flow (fiscal 2025) | $2.1B | | Dividend yield (trailing twelve months) | 0.00% | | Beta | 1.17 | | Cost of capital (WACC) | 8.28% | | Business classification | Mature & Stable (Low/slowing growth (~4% recent), Moderate margins (8% net margin), Highly cyclical earnings, High leverage (D/E 2.4x)) | ## On the stock lists | List | Place | Figure | Page | | --- | ---: | ---: | --- | | Near 52-week highs | #48 | −1.8% | https://sweetvaluelab.com/lists/near-52-week-highs | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $237.57 | $131.30 | $621.45 | | DCF · Perpetuity growth · 10y | cross check | $262.39 | $152.60 | $652.71 | | DCF · EBITDA exit · 5y | cross check | $468.89 | $351.74 | $605.87 | | DCF · EBITDA exit · 10y | cross check | $458.02 | $323.12 | $634.92 | | P/E · peers | cross check | $357.78 | $226.40 | $489.16 | | P/E · own history | cross check | $343.10 | $283.44 | $410.44 | | PEG | sanity check | $276.83 | $276.83 | $276.83 | | EV/EBITDA · peers | cross check | $563.64 | $532.33 | $707.97 | | EV/Revenue · peers | cross check | $216.29 | $163.20 | $294.63 | | Earnings power value | cross check | $8.24 | $0.00 | $27.59 | | Dividend discount | cross check | $0.00 | $0.00 | $0.00 | ## Insider activity (SEC Form 4) Past 90 days: 0 open-market buys ($0) and 9 open-market sales ($29.9M); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 2, 2026 | Berkshire James G. | See Remarks | Option/RSU exercise | 5,381 | $709,323.4 | | Sep 2, 2026 | Berkshire James G. | See Remarks | Open-market sell | 2,668 | $697,228.4 | | Sep 2, 2026 | Berkshire James G. | See Remarks | Disposition to issuer | 2,713 | $709,558 | | Sep 2, 2026 | Berkshire James G. | See Remarks | Option/RSU exercise | 5,381 | $709,323.4 | | Aug 3, 2026 | STAUB W RICHARD | See Remarks | Open-market sell | 5,500 | $1.3M | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Sep 23, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1478242/000119312526399616/d128109d8k.htm | | Sep 9, 2026 | 8-K | 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1478242/000119312526386633/d516985d8k.htm | | Jul 28, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1478242/000162828026050211/iqv-20260630.htm | | Jul 28, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/iqv-20260728.htm | | Jun 11, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1478242/000119312526267763/d157492d8k.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Bill Nygren | 2026-06-30 | 12,183,830 | $2.4B | | Greenhaven | 2026-06-30 | 768,045 | $148.4M | | Vulcan Value | 2026-06-30 | 259,856 | $50.2M | | Thomas Gayner | 2026-06-30 | 46,900 | $9.1M | 5 tracked managers in all. ## About IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercia… --- Source: https://sweetvaluelab.com/stocks/iqv (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.